LENZ Therapeutics (LENZ) Change in Account Payables (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Change in Account Payables data on file, last reported at $6.8 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 977.04% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $7.4 million, a 296.85% increase from a year earlier, with the FY2025 full-year figure at -$90000.0, up 97.9% from the prior year.
• Change in Account Payables for Q1 2026 stood at $6.8 million, up from -$156000.0 in the prior quarter.
• Over the last five years, Change in Account Payables for LENZ reached as high as $6.8 million in Q1 2026 and fell as low as -$2.7 million in Q2 2024.
• Historically, Change in Account Payables has averaged $202529.4 across 5 years, with a median of -$156000.0 in 2025.
• Across the five-year window, Change in Account Payables sank 642.86% in 2023 and surged 977.04% in 2026, its largest moves.
• Year by year, Change in Account Payables stood at -$1.1 million in 2022, then soared by 200.65% to $1.1 million in 2023, then climbed by 21.32% to $1.3 million in 2024, then slumped by 111.82% to -$156000.0 in 2025, then jumped by 4434.62% to $6.8 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $6.8 million in Q1 2026, -$156000.0 in Q4 2025, and $1.7 million in Q3 2025.